Bleeding after antithrombotic therapy in patients with acute ischemic heart disease

Journal of Thrombosis and Thrombolysis

Volumn 26, Issue 3, 2008, Pages 175-182

  Cohen, Marc ^a   Alexander, Karen P ^b   Rao, Sunil V ^b  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Bleeding; Hemorrhage; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HEMATOCRIT; HEMODYNAMICS; HUMAN; IMPLANTATION; INCIDENCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; STENT;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SEX FACTORS;

EID: 56649091378     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0182-x     Document Type: Article

References (35)

1. Rao SV, Jollis JG, Harrington RA et al (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292:1555-1562
2. Rao SV, O'Grady K, Pieper KS et al (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200-1206
3. Eikelboom JW, Mehta SR, Anand SS, Xie C et al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774-782
4. Sabatine MS, Cannon CP, Gibson CM et al, for the CLARITY-TIMI 28 Investigators (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179-1189
5. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-1476
6. Antman EM, Morrow DA, McCabe CH et al, for the ExTRACT-TIMI 25 Investigators (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354:1477-1488
7. Montalescot G, White HD, Gallo R et al, for the STEEPLE Investigators (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. New Engl J Med 355:1006-1017
8. Stone GW, McLaurin BT, Cox, DA et al, for the ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203-2216
9. Moscucci M, Fox KAA, Cannon CP et al, for the GRACE Investigators (2003) Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24:1815-1823
10. Farouque HM, Tremmel JA, Raissi Shabari F et al (2005) Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J Am Coll Cardiol 45:363-368
11. Yang X, Alexander KP, Chen AY et al, for the CRUSADE Investigators (2005) Blood transfusion and non-ST-segment elevation acute coronary syndromes: Results from CRUSADE. J Am Coll Cardiol 46:1479-1487
12. Manoukian SR, Feit F, Mehran R et al (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes, An analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362-1368
13. Alexander KP, Chen AY, Roe MT et al, for the CRUSADE Investigators (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108-3116
14. Alexander KP, Chen AY, Newby LK et al, for the CRUSADE Investigators (2006) Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 114:1380-1387
15. GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682
16. Lincoff AM, Bittl JA, Harrington RA et al, for the REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-863
17. Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142-154
18. Ferguson JJ, Califf RM, Antman EM et al, for the SYNERGY Trial Investigators (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 292:45-54
19. Cohen M, Demers C, Gurfinkel EP et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337:447-452
20. Peterson ED, Coombs LP, DeLong ER, Haan CK, Ferguson TB (2004) Procedural volume as a marker of quality for CABG surgery. JAMA 291:195-201
21. The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339:436-443
22. Boersma E, Harrington RA, Moliterno DJ et al (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 359:189-198
23. Peters RJG, Mehta SR, Fox KAA et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682-1687
24. Bovill EG, Terrin ML, Stump DC et al (1991) Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115:256-265
25. Rao SV, O'Grady K, Pieper KS et al (2006) A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47:809-816
26. Majure DT, Aberegg SK (2006) Fondaparinux versus enoxaparin in acute coronary syndromes. N Engl J Med 354:2829; author reply 2830
27. Fox KAA, Bassand JP, Wallentin L et al (2006) The Efficacy and Safety of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome: Impact of Renal Dysfunction (OASIS 5). ACC 2006, presentation #972-222, presented 13 Mar 2006
28. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction)
29. Kaul S, Shak PK, Diamond GA (2006) Bivalirudin during early invasive strategy for acute coronary syndromes: Noninferiority in ACUITY lies in the eyes of the beholder. Circulation 114:II-552: (abstr 2652)
30. Kirtane AJ, Piazza G, Murphy SA et al, for the TIMI Study Group (2006) Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: Observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47:2374-2379
31. EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961
32. Smith SC Jr., Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosElerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363-2372
33. EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87-92
34. ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 356:2037-2044
35. Bhatt DL, Fox KA, Hacke W, et al, for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-1717